Daniel G. Gioeli, PhD
Peptide growth factor and androgen signaling cross-talk and contribution to progression of prostate cancer from androgen-dependent to androgen-independent disease
The overall goal of Dr. Gioeli's research group is to understand how peptide growth factor and androgen signaling cross-talk and contribute to the progression of prostate cancer from an androgen-dependent to an androgen-independent disease. The group is exploring the hypothesis that growth factors and androgen signaling alter AR activity through regulated changes in phosphorylation of the AR or of AR-associated proteins, and that these regulated changes help drive prostate cancer progression from an androgen-dependent disease to one that is androgen-independent. Dr. Gioeli was the first one to systematically identify the AR phosphorylation sites in response to androgen and growth factors. His laboratory is currently assessing the role of AR phosphorylations in AR function, identifying AR kinases, and assessing the level of AR phosphorylation in prostate cancer material. This work is being pursued collaboratively with Drs Michael Weber, Bryce Paschal, and Henry Frierson. Dr. Gioeli is also developing a tissue specific siRNA delivery system as a targeted prostate cancer therapy. This work is in collaboration with Dr. Cassandra Fraser in the Chemistry Department to develop polymeric metal complexes as a therapeutic platform. Dr Gioeli's studies will utilize the Tissue Procurement Core, Research Histology Core, DNA Science Core, Cell Sorter Facility, Center for Advanced Microscopy, Biostatistical Core, and Molecular Therapeutics Core. Dr. Gioeli's research is basic to understanding the mechanism of how signal transduction activity regulates AR transactivation and is fundamental developing targeted therapies for androgen-independent prostate cancer.